Octreotide therapy in carcinoid disease

Bax, N. D. S.; Hf, Woods; Batchelor, A.G.; Jennings, Marian

doi:10.1097/00001813-199601001-00004

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the effect of SST analogues on 24-h urinary 5-hydroxyindoleacetic acid values in patients with carcinoid syndrome is inconsistent and does not always predict the response to treatment. [27][28][29][30][31] Sandostatin LAR did not appear to interfere with octreotide imaging and, when other treatments were given, e.g. high-dose indium-111 octreotide or yttrium-90-labelled Lanreotide, there was no evidence to suggest this affected the uptake of the radio-labelled preparation by the tumour.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Sandostatin LAR (long‐acting octreotide acetate) for malignant carcinoid syndrome: a 3‐year experience

Garland¹,

Buscombe²,

Bouvier³

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Somatostatin analogues are the best therapy for controlling the symptoms of malignant carcinoid syndrome. Octreotide acetate given as subcutaneous injection up to three times daily, intramuscular Lanreotide injection given once per 1-2 weeks and monthly intramuscular Sandostatin LAR have demonstrated similar efficacy in short-term studies. Aim: To assess the long-term effect of Sandostatin LAR on the management of patients with malignant carcinoid syndrome. Methods: This was a 3-year retrospective study. Twenty-seven patients were assessed with a median follow-up of 23 months. Thirteen patients were switched from subcutaneous octreotide and 14 patients

show abstract

Section: Discussionmentioning

confidence: 93%

“…We did not have complete data on 24‐h urinary 5‐hydroxyindoleacetic acid values for all patients. However, the effect of SST analogues on 24‐h urinary 5‐hydroxyindoleacetic acid values in patients with carcinoid syndrome is inconsistent and does not always predict the response to treatment 27–31 …”

Section: Discussionmentioning

confidence: 99%

Sandostatin LAR (long‐acting octreotide acetate) for malignant carcinoid syndrome: a 3‐year experience

Garland¹,

Buscombe²,

Bouvier³

et al. 2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Hormone therapy is indicated in carcinoids causing functional symptoms, however, no evidence is available as to the control of disease progression. Moreover, this therapy might only exert cytostatic effects [23][24][25] . Indeed, evidence does exist demonstrating that somatostatin analogs can inhibit tumour growth, at least for a certain period of time [26,27] , but further studies are necessary to evaluate this effect.…”

Section: Discussionmentioning

confidence: 99%

Primary hepatic carcinoid: A case report and literature review

Fenoglio¹,

Severini²,

Ferrigno³

et al. 2009

WJG

View full text Add to dashboard Cite

Carcinoids are tumors derived from neuroendocrine cells and often produce functional peptide hormones. Approximately 54.5% arise in the gastrointestinal tract and frequently metastasize to the liver. Primary hepatic carcinoid tumors (PHCT) are extremely rare; only 95 cases have been reported. A 65-year-old man came to our attention due to occasional ultrasound findings in absence of clinical manifestations. His previous medical history, since 2003, included an echotomography of the dishomogeneous parenchymal area but no focal lesions. A computed tomography s c a n p e r fo r m e d i n 2 0 0 5 s h o w e d an enhanced pseudonodular-like lesion of about 2 cm. Cholangiomagnetic resonance imaging identified the lesion as a possible cholangiocarcinoma. No positive findings were obtained with positron emission tomography. Histology suggested a secondary localization in the liver caused by a low-grade malignant neuroendocrine tumor. Immunohistochemistry was positive for anti chromogranin antibodies, Ki67 antibodies and synaptophysin. Octreoscan scintigraphy indicated intense activity in the lesion. Endoscopic investigations were performed to exclude the presence of extrahepatic neoplasms. Diagnosis of PHCT was established. The patient underwent left hepatectomy, followed by hormone therapy with sandostatine LAR. Two months after surgery he had a lymph nodal relapse along the celiac trunk and caudate lobe, which was histologically confirmed. The postoperative clinical course was uneventful, with a negative follow-up for hematochemical, clinical and radiological investigations at 18 mo post-surgery. Diagnosis of PHCT is based principally on the histopathological confirmation of a carcinoid tumor and the exclusion of a non-hepatic primary tumor. Surgical resection is the recommended primary treatment for PHCT. Recurrence rate and survival rate in patients treated with resection were 18% and 74%, respectively.

show abstract

“…Octreotide has a half life of several hours, making intermittent therapy possible. This drug is administered by subcutaneous injection starting at 50-100 mg twice or three times a day to a maximum daily dose of 1500 mg. 120 More recently, analogues with sustained release from depot injections have been synthesised and these are given every 2-4 weeks. 121 These drugs, lanreotide (fortnightly injection), Sandostatin LAR (monthly), and Lanreotide Autogel (also monthly), have shown significant improvement in the quality of life of patients and have as good or better efficacy compared with short acting octreotide.…”

Section: Symptomatic Treatmentmentioning

confidence: 99%